Recommendations of the German, Austrian and Swiss rheumatology and other medical societies for the management of polymyalgia rheumatica
These updated recommendations should serve as an aid to evidence-based decisions ensuring high-quality care for all patients with PMR.
Authors
- Thomas Daikeler
- Ulrike Erstling (ORCID: https://orcid.org/0009-0000-3565-2410)
- Diego Kyburz (ORCID: https://orcid.org/0000-0002-9560-109X)
- Kathrin Scheuermann
- Anett Reißhauer (ORCID: https://orcid.org/0009-0009-9437-4858)
- Eric L. Matteson (ORCID: https://orcid.org/0000-0002-9866-0124)
- Christina Duftner (ORCID: https://orcid.org/0000-0003-3137-8834)
- Frank Buttgereit (ORCID: https://orcid.org/0000-0003-2534-550X)
- Thomas Brabant
- Ulrike Garske
- Patricia Steffens-Korbanka
- Christian Dejaco (ORCID: https://orcid.org/0000-0002-0173-0668)
- Bernhard Hellmich (ORCID: https://orcid.org/0000-0002-8014-1801)
- Zhivana Boyadzhieva (ORCID: https://orcid.org/0000-0002-6708-0688)
- Myriam Reisch
- Matthias Schneider (ORCID: https://orcid.org/0000-0002-2655-3709)
- Monika Reuß‐Borst
Institutions
- Mayo Clinic (US)
- Innsbruck Medical University (AT)
- Osnabrück University (DE)
- University of Basel (CH)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
- University Hospital of Basel (CH)
- Humboldt-Universität zu Berlin (DE)
- Kantonsspital Baselland (CH)
- Universitätsklinikum Tübingen (DE)
- Deutsche Rheuma-Liga (DE)
- Mayo Clinic in Arizona (US)
- Hewlett-Packard (Germany) (DE)
- Federal Highway and Transport Research Institute (DE)
- Center for Rheumatology (US)
- Heinrich Heine University Düsseldorf (DE)
- Praxis (EE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1093/rheumatology/keaf646
- Citations
- 1
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Biogen
- Alexion Pharmaceuticals
- Horizon Therapeutics
- Swedish Orphan Biovitrum
- Medac
- AOP Orphan
- InflaRx
- National Institutes of Health
- Chugai Pharmaceutical
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Cilag